Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
Adam Jacob Schoenfeld, Kathryn Cecilia Arbour, Hira A. Rizvi et al. · Annals of Oncology · 2019
Cited by 404 works. doi:10.1093/annonc/mdz077 Open-access PDF
Authors
- Adam Jacob Schoenfeld
- Kathryn Cecilia Arbour
- Hira A. Rizvi
- Afsheen N. Iqbal
- Shirish M. Gadgeel
- Jeffrey Girshman
- Mark G. Kris
- Gregory J. Riely
- Helena Alexandra Yu
- Matthew David Hellmann
References
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
- EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer